Suchergebnisse - "Othman, Ahmed A"

PubPharm (26)

1

Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

enthalten in: Journal of clinical pharmacology | 2021

von Mohamed, M. | Gopalakrishnan, S. | Teixeira, H. | +1

2

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease

enthalten in: Gastroenterology | 2020

von Sandborn, W. | Feagan, B. | Loftus, E. | +19

CommentIn: Gastroenterology. 2021 Apr;160(5):1472-1474. - PMID 32311362

3

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

enthalten in: Gastroenterology | 2020

von Sandborn, W. | Ghosh, S. | Panes, J. | +9

CommentIn: Gastroenterology. 2021 Apr;160(5):1472-1474. - PMID 32311362

4

Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis

enthalten in: Clinical pharmacokinetics | 2020

von Suleiman, A. | Khatri, A. | Oberoi, R. | +1

5

Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis

enthalten in: Clinical pharmacology and therapeutics | 2020

von Nader, A. | Mohamed, M. | Winzenborg, I. | +4

6

Upadacitinib in adults with moderate to severe atopic dermatitis : 16-week results from a randomized, placebo-controlled trial

enthalten in: The Journal of allergy and clinical immunology | 2020

von Guttman-Yassky, E. | Thaçi, D. | Pangan, A. | +10

7

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation

enthalten in: Clinical pharmacology and therapeutics | 2020

von Mohamed, M. | Klünder, B. | Lacerda, A. | +1

8

Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

enthalten in: Clinical pharmacology and therapeutics | 2020

von Khatri, A. | Suleiman, A. | Polepally, A. | +1

9

Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

enthalten in: Clinical pharmacology and therapeutics | 2019

von Mohamed, M. | Klünder, B. | Camp, H. | +1

10

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis : Integrated Analyses of Phase I-III Clinical Trials

enthalten in: Clinical pharmacokinetics | 2019

von Suleiman, A. | Minocha, M. | Khatri, A. | +2